Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.46

0.11 (0.37%)

05:38
10/19/16
10/19
05:38
10/19/16
05:38

Roche announces FDA approval of TECENTRIQ

Roche announced that the FDA approved TECENTRIQ for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has EGFR or ALK gene abnormalities. This approval is based on results from the randomised Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy. The study enrolled people regardless of their PD-L1 status and included both squamous and non-squamous disease types.

  • 19

    Oct

  • 19

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.46

0.11 (0.37%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$98.12

1.92 (2.00%)

15:31
09/21/17
09/21
15:31
09/21/17
15:31
Recommendations
Intercept analyst commentary  »

Intercept selloff and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$21.42

-0.03 (-0.14%)

15:30
09/21/17
09/21
15:30
09/21/17
15:30
Options
Bullish flow continues for a third day in Michaels Companies »

Bullish flow continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
09/21/17
09/21
15:17
09/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/21/17
09/21
15:16
09/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/21/17
09/21
15:15
09/21/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

15:10
09/21/17
09/21
15:10
09/21/17
15:10
General news
Fedspeak is heavy next week, with 12 Committee members scheduled »

Fedspeak is heavy next…

CSX

CSX

$52.81

1.03 (1.99%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Hot Stocks
CSX says service 'rapidly' restored following Hurricane Irma »

CSX said that following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

GE

General Electric

$24.65

0.33 (1.36%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Options
General Electric call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ICPT

Intercept

$98.12

1.92 (2.00%)

15:00
09/21/17
09/21
15:00
09/21/17
15:00
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.70

-0.46 (-3.25%)

14:57
09/21/17
09/21
14:57
09/21/17
14:57
Periodicals
Snap cuts headcount at hardware lab, maker of spectacles, Bloomberg says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$43.73

-0.44 (-1.00%)

14:55
09/21/17
09/21
14:55
09/21/17
14:55
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

14:55
09/21/17
09/21
14:55
09/21/17
14:55
General news
Canada CPI preview »

Canada CPI preview: CPI,…

14:50
09/21/17
09/21
14:50
09/21/17
14:50
General news
Canada retail sales preview »

Canada retail sales…

ICPT

Intercept

$98.12

1.92 (2.00%)

14:49
09/21/17
09/21
14:49
09/21/17
14:49
Recommendations
Intercept analyst commentary  »

Citi calls FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

PSTG

Pure Storage

$15.32

0.49 (3.30%)

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Options
Pure Storage call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

NLSN

Nielsen

$40.48

0.06 (0.15%)

, CBS

CBS

$58.90

-0.155 (-0.26%)

14:44
09/21/17
09/21
14:44
09/21/17
14:44
Hot Stocks
CBS to use Nielsen Out-of-Home Reporting Service »

Nielsen (NLSN) announced…

NLSN

Nielsen

$40.48

0.06 (0.15%)

CBS

CBS

$58.90

-0.155 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Nov

ALNY

Alnylam

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Alnylam CEO 'confident' patisiran is best-in-class treatment »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.82

0.82 (1.34%)

, NVS

Novartis

$85.01

-0.77 (-0.90%)

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Express Scripts CMO discusses 'great promise, big price' of gene therapy »

In a post to the…

ESRX

Express Scripts

$61.82

0.82 (1.34%)

NVS

Novartis

$85.01

-0.77 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Oct

  • 08

    Nov

  • 17

    May

ALNY

Alnylam

$113.84

38.8 (51.71%)

14:40
09/21/17
09/21
14:40
09/21/17
14:40
Hot Stocks
Alnylam CEO says more confident in other trials after patisiran data »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTX

Minerals Technologies

$69.50

1.1 (1.61%)

14:33
09/21/17
09/21
14:33
09/21/17
14:33
Hot Stocks
Minerals Technologies authorizes $150M, two-year share repurchase program »

Minerals Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$48.01

-0.345 (-0.71%)

14:30
09/21/17
09/21
14:30
09/21/17
14:30
Options
Short-term put buying in Harley Davidson »

Short-term put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 17

    Oct

ICPT

Intercept

$98.12

1.92 (2.00%)

14:25
09/21/17
09/21
14:25
09/21/17
14:25
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept breaks $80,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

14:25
09/21/17
09/21
14:25
09/21/17
14:25
Options
HCA Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.40

5.41 (4.75%)

14:24
09/21/17
09/21
14:24
09/21/17
14:24
Periodicals
ILG may have proxy fight without deal with Marriott Vacations, Bloomberg says »

ILG is facing pressure…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.40

5.41 (4.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.